(Q24243197)

title

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

12 May 2020

0 references

0 references

1

T A Furukawa

T A

Furukawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

12 May 2020

N Watanabe

2

N

Watanabe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

12 May 2020

R Churchill

series ordinal

3

author given names

R

author last names

Churchill

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

Cochrane Database of Systematic Reviews

12 May 2020

language of work or name

1 reference

24 January 2007

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

12 May 2020

page(s)

CD004364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

12 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

12 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

The effect of pharmacotherapist characteristics on treatment outcome in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

The Galway Study of Panic Disorder. III. Outcome at 5 to 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Combined behavioral therapy and pharmacotherapy of agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Imipramine in the treatment of agoraphobia: dose-response relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Treatment-outcome research in panic disorder: dilemmas in reconciling the demands of pharmacological and psychological methodologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Autonomic changes after treatment of agoraphobia with panic attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Differential treatment of phobias: Use of imipramine for panic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Panic and avoidance in agoraphobia. Application of path analysis to treatment studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Treatment of phobias. II. Behavior therapy and supportive psychotherapy: are there any specific ingredients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Behavior Therapy, Supportive Psychotherapy, Imipramine, and Phobias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Exposure and communications training in the treatment of agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Flooding with brevital in the treatment of agoraphobia: Countereffective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Surreptitious drug use by patients in a panic disorder study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

How study design affects outcomes in comparisons of therapy. I: Medical

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials.

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

21 January 2018

12 December 2020

The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Flawed Meta-Analyses Comparing Psychotherapy With Pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Empirically supported treatments for panic disorder: costs, benefits, and stepped care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Combined psychotherapy plus benzodiazepines for panic disorder with or without agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

The cross-national epidemiology of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants

21 January 2018

1 reference

12 December 2020

The managment of severe agoraphobia: a comparison of iproniazid and systematic desensitization

1 reference

12 December 2020

A meta-analysis of treatments for panic disorder

1 reference

12 December 2020

WCA recommendations for the long-term treatment of panic disorder.

1 reference

12 December 2020

Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder

2 references

12 December 2020

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

7 January 2021

inferred from DOI database lookup

Duration of imipramine therapy and relapse in panic disorder with agoraphobia

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.

1 reference

12 December 2020

Imipramine and Brief Therapist-Aided Exposure in Agoraphobics Having Self-exposure Homework

1 reference

12 December 2020

Phenelzine and exposure in the treatment of phobias

1 reference

12 December 2020

Comparison of short-term treatment regimens in phobic patients: a preliminary report

1 reference

12 December 2020

Specific phobia 10-16 years after treatment

1 reference

12 December 2020

Two-year follow-up of exposure and imipramine treatment of agoraphobia

1 reference

12 December 2020

Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone

1 reference

12 December 2020

Overcoming resistance to exposure in panic disorder with agoraphobia

1 reference

12 December 2020

Clomipramine treatment and behaviour therapy with agoraphobic women

1 reference

12 December 2020

A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments

1 reference

12 December 2020

How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.

1 reference

12 December 2020

Two-year follow-up of agoraphobics after exposure and imipramine

1 reference

12 December 2020

The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial

1 reference

12 December 2020

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

1 reference

12 December 2020

Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment

1 reference

12 December 2020

Long-term outcome of panic disorder with agoraphobia treated by exposure.

1 reference

12 December 2020

Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo

1 reference

12 December 2020

Combined pharmacological and behavioral treatment for agoraphobia

1 reference

12 December 2020

Pretreatment attrition in a comparative treatment outcome study on panic disorder

1 reference

12 December 2020

Effects of panic disorder treatments on personality disorder characteristics

1 reference

12 December 2020

Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up

1 reference

12 December 2020

Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings

1 reference

12 December 2020

Agoraphobics 5 years after imipramine and exposure. Outcome and predictors

1 reference

12 December 2020

Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association

1 reference

12 December 2020

Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine.

1 reference

12 December 2020

Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care

1 reference

12 December 2020

Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors

1 reference

12 December 2020

Treatment of panic and agoraphobia. An integrative review

1 reference

12 December 2020

Effects of panic disorder treatments on personality disorder characteristics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

7 January 2021

inferred from DOI database lookup

Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004364.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD004364.PUB2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

release_k4iklz7s7jdcba6ubacdhdw6am

12 May 2020

Fatcat ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823237&resulttype=core&format=json

12 May 2020

1 reference